Introduction
Globally, cancers of the colon and rectum are the third and fourth leading causes of cancer deaths in males and females, respectively 1 . Chemotherapeutic agents are the main tools for treating cancer. However, most of these drugs are nonspecific, or become less effective as tumor cells acquire multi-drug resistance. Therefore, numerous trials have been performed to enhance the therapeutic effectiveness and reduce the side effects of chemotherapeutic agents. Currently, the most common strategy for enhancing anti-cancer treatments is the use of sensitizers or drug combinations. If detected early, colon cancer is treatable; however, metastatic colon cancer is associated with high mortality. In combination with the first-choice chemotherapy agent 5-fluorouracil, new drugs, such as irinotecan, oxaliplatin, bevacizumab, and cetuximab, have improved the outcome of advanced colon cancer 2 . However, prognosis for metastatic colon cancer remains very poor. Therefore, novel therapeutic options are needed to reduce colon cancer mortality.
PPARγ is a nuclear receptor that plays an essential role in lipid and glucose homeostasis 3 , cell proliferation 4 , apoptosis 5 , and inflammation 6 . Upon agonist binding, PPARγ becomes activated and forms a heterodimer with RXRα. The PPARγ-RXRα heterodimer translocates to the nucleus and binds to the peroxisome proliferator response element (PPRE;
TGACCTnTGACCT) in the promoter region of target genes. Once bound, the heterodimer recruits the coactivators SRC-1, CBP, and TRAP220, and the corepressors NCoR and SMRT, to modulate gene transcription 7 8 9 . A variety of physiological and synthetic PPARγ agonists have been identified. Physiological agonists include 15d-PGJ 2 10 , selected forms of lysophospholipids, such as lysophosphatidic acid (LPA) 11 and alkyl glycerophosphate (AGP) 12 , oxidized cPA on cell growth inhibition in the human colon cancer cell line HT-29. We also provide the first evidence that PPARγ is required in cell growth inhibition induced by cPA. Thus, cPA and its analogs could serve as new drug candidates for the treatment of colon cancer.
Materials and methods

2-1. Reagents and antibodies
cPA (18:1 and 16:0) was purchased from Avanti Polar Lipids Inc. (Alabaster, AL, USA). cPA purity was confirmed by negative ion liquid chromatography-mass spectrometry (data not shown). cPA was quantified by the molybdenum blue method 30 , and prepared as a 10 mM stock in dimethylsulfoxide (DMSO). ROSI was purchased from ALEXIS Biochemicals (Lausen, Switzerland), and prepared as a 10 mM stock in ethanol. The cPA carba derivative (3ccPA 16:1) and cPA 17:0 were chemically synthesized as described previously ( Anti-mouse IgG secondary antibody was from Calbiochem (San Diego, CA, USA).
2-2. Plasmids and vectors
The pSV40-β-galactosidase (Promega) and pcDNA3.1 plasmids were purchased from Promega and Invitrogen Corp. (Carlsbad, CA, USA), respectively. The pcDNA3.1-PPARγ and pGL3b-PPRE (ACO)-Fluc plasmids were constructed as described previously 12 . Transfection of plasmid DNA was performed using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions.
2-3. Cell culture and transfection
2-4. Growth curve studies
A dose-response growth curve was performed to determine the concentration of saturated or unsaturated cPA necessary to significantly inhibit cell growth. HT-29 cells (2 × 10 4 cells/well)
were plated in a monolayer on 6-well tissue culture plates. The next day, DMEM containing 1-100 µM cPA 18:1 or cPA 16:0 was added. Five days after cPA treatment, the cells were trypsinized and counted using a hematocytometer. Cell numbers were expressed as percentage of untreated controls.
2-5. MTT and EdU incorporation assays
Cell proliferation was measured by MTT and EdU incorporation assays. Cells were plated onto 96-well plates (Iwaki, Tokyo, Japan) and treated with cPA and/or ROSI, with or without overnight serum starvation, as described in figure legends. Cell proliferation was then determined using the Cell Proliferation Kit I (MTT; Roche Applied Science, Indianapolis, IN, USA) or the Click-iT EdU Microplate Assay Kit (Invitrogen), following the manufacturers'
instructions.
2-6. Western blot analysis
Cells were seeded onto 6-well plates (Iwaki) at a density of 4 × 10 4 cells/well. After being treated as indicated, cells were lysed on ice for 30 min in cell lysis buffer containing 20 mM Tris-HCl (pH 7.4), 10% (v/v) glycerol, 100 mM NaCl, 1% (v/v) Triton X-100, 1:100 protease inhibitor cocktail (Sigma-Aldrich), and 1 mM dithiothreitol. After lysis, cells were centrifuged at 16,000 × g for 20 min at 4°C. The supernatants containing cell lysates were assayed for protein content by the Bradford method using the Bio-Rad Protein Assay kit (Bio-Rad Laboratories, Hercules, CA, USA). The lysates were separated on 10% SDS-polyacrylamide gels and transferred onto Immobilon-P membranes (Millipore, Billerica, MA, USA). The membranes were blocked with 5% (w/v) non-fat dried milk in 20 mM Tris-HCl (pH 7.5), 100 mM NaCl, and 0.05% (v/v) Tween 20 (TBS-T) for 1 h, and incubated with primary antibody in TBS-T with 5% non-fat dried milk for 12 h at 4°C. Bands were visualized with the Amersham ECL-Plus Western Blot Detection Reagents (GE Healthcare).
2-7. Reporter gene assay
To determine endogenous PPARγ activation, HT-29 cells were co-transfected with pGL3b-PPRE (ACO)-Fluc and pSV40-β-galactosidase plasmids, and reporter gene expression was determined as previously described 12 . Twenty-four hours after transfection, cells were treated with the indicated compounds and incubated for an additional 20 h. Luciferase activity
was measured with the Steady-Glo Luciferase Assay System (Promega) using the SpectraMax plate reader (Molecular Devices, Sunnyvale, CA, USA).
2-8. Preparation of subcellular fractions
Following serum starvation, HT-29 cells were treated with DMSO or 10 µM cPA 18:1, cPA 16:0, or 3ccPA 16:1 for 20 min or 1 h at 37°C, rinsed twice with phosphate-buffered saline (PBS), and harvested by scraping. The NE-PER TM Cell Fractionation Kit (Pierce Biotechnology, Rockford, IL, USA) was used to isolate the nuclear fraction from the cells, according to the manufacturer's instructions. After the cytosolic fraction was separated, the nuclear fraction was subjected to a brief centrifugation, and the interface was removed to reduce cytoplasmic contamination. The cytoplasmic and nuclear fractions were tested for purity by immunoblotting for HSP90 (cytoplasmic marker) and p53 (nuclear marker), and stored at -80°C until use.
2-9. Quantitative determination of cPA in nuclear fractions by ESI-LC-MS
Lipids were extracted using the Bligh and Dyer method as previously described 33 . The extracted lipids were dissolved in 0.1 mL of methanol/chloroform/28% NH 4 OH (90:10:0.1), and immediately analyzed by electrospray ionization, liquid chromatography-mass spectrometry (ESI-LC-MS). Liquid chromatography-mass spectrometry (LC-MS) was performed on an LCMS-2010A mass spectrometer (Shimadzu, Kyoto, Japan) equipped with an Econosphere 3 µm, 50 × 4.6 mm silica column (Alltech Associates Inc., Deerfield, IL, USA). The sample was maintained at 250°C with drying gas flow of 1.5 L/min, and data were collected in the negative ion mode from 100 to 1000 m/z. cPA was quantified by comparing the [M-H] -signal intensity of cPA to that of the internal standard cPA 17:0.
2-10. Hoechst staining assay
Intact HT-29 cells were stained with Hoechst 33342 (Dojindo, Kumamoto, Japan, 5 µg/mL) for 10 min and analyzed on an Olympus IX71 fluorescence microscope (Tokyo, Japan) with excitation at 360 nm. With Hoechst staining, viable cells were observed with intact nuclei, and apoptotic cells with fragmented or condensed nuclei.
2-11. Inhibition of PPARγ function using small interfering RNA
PPARγ expression was inhibited in HT-29 cells by transfection with a small interfering RNA (siRNA) targeting PPARγ , using Lipofectamine RNAiMAX (Invitrogen). siRNA not specific to any sequence was used as the negative control. Reduction of PPARγ levels was confirmed by western blot analysis as described above.
2-12. Statistical analysis
Student's t-test was used to make statistical comparisons. Differences were considered significant when the p-value was below 0.05.
Results
3-1. PPARγ activation does not inhibit HT-29 cell growth
We first examined the ability of ROSI, a PPARγ agonist, to inhibit proliferation of several cancer cell lines. Fig. 2A shows the effect of ROSI on cancer cell growth after a 72-h treatment.
At concentrations below 20 µM, ROSI inhibited cell growth in HeLa cells, B16F10 cells, U-937 cells, and HL-60 cells, but had no effect on the growth of HT-29. We then investigated PPARγ protein levels in different cancer cell lines listed here (Fig. 2B ). The only PPARγ isoform detected was PPARγ 1 . Three isoforms of PPARγ have been identified in humans:
PPARγ 1 , PPARγ 2 , and PPARγ 3 . The biological significance of our finding only PPARγ 1 is unclear, since the functional differences among the PPARγ isoforms are unknown. Next, to test the functionality of the PPARγ receptor, we transfected the above cell lines with a luciferase reporter plasmid. After ROSI treatment, we observed increased luciferase activity (Fig. 2B ).
3-2. cPA inhibits HT-29 cell growth by inhibiting PPARγ
As shown in Figs. 3A and B, cPA inhibited cell growth in a dose-and time-dependent manner.
cPA 18:1 (unsaturated form) and cPA 16:0 (saturated form) inhibited cell growth with IC 50 of 10 µM and 4.5 µM, respectively. cPA 18:1 has 1 double bond in the carbon chain, and that double bond may react with oxygen. Hence, we decided to use the saturated form of cPA (16:0) and the metabolically stabilized cPA carba derivative (3ccPA 16:1), in which the phosphate oxygen is replaced with a methylene group, to define the role of cPA in the regulation of cell cell growth any more than did treatment with cPA alone.
3-3. cPA induces DNA condensation
Next, we confirmed nuclear distribution of exogenous cPA in HT-29 cells, using ESI-LC-MS.
Interestingly, the nuclear fraction of HT-29 cells was found to contain significant amount of AGP (Fig. 4A ). AGP is a PPARγ agonist 12 in HT-29 cells, constitutively activating PPARγ. We then examined the amount cPA present in the cells. cPA 18:1 was added to cells at a concentration of 10 µM, and lipid uptake was determined by ESI-LC-MS. As shown in Fig. 4B , time-dependent accumulation of cPA 18:1 was detected in the nuclei. The same experiments were repeated with exogenous cPA 16:0 and ccPA 16:1 (Fig. 4B) .
Recent studies have shown that inhibiting PPARγ with a synthetic antagonist (T0070907 or GW9662) caused apoptosis by preventing of cellular adhesion 17 . Light microscopy analysis of HT-29 cells revealed that treatment with cPA and its derivative induced cell detachment after 96 h (Fig. 4D ). Hoechst 33342 staining demonstrated that treatment with cPA increased DNA condensation, and therefore apoptosis, by approximately 8-fold as compared to the vehicle control (Fig. 4E ).
Discussion
We recently reported that cPA ( Fig. 1) reported that GW9662 prevented PPARγ activation and proliferation of breast cancer cell lines.
T0070907 was identified as a potent and selective PPARγ antagonist 40 , and reduced colon cancer migration and invasion in a xenograft metastatic model 27 . These data indicated that the increase in floating cells upon cPA treatment (Fig. 4F ) was due to the induction of apoptosis.
PPARγ-mediated transcriptional repression may explain some of the effects of cPA and ccPA.
Our current proposed mechanism for cPA action is presented in Fig. 5 
